Dubbed DermCeutical PNar, Debut’s new biotech active ingredient is designed to target hyperpigmentation through a molecular design approach that combines AI, skin genomics and biotechnology.
According to the company, the ingredient works by targeting the biological drivers of hyperpigmentation, including inhibiting tyrosinase and other enzymes involved in melanin production, with the aim of preventing the formation of dark spots before they appear.
Beyond kojic acid
The launch comes as brands face evolving regulatory requirements for established depigmenting ingredients. Debut highlights recent EU restrictions limiting kojic acid to a maximum concentration of 1% in face and hand care products, following concerns over potential endocrine-disrupting properties and dermal absorption.
The company positions PNar as an alternative capable of delivering efficacy at a 0.45% use level — less than half the EU’s maximum permitted concentration for kojic acid in skincare applications.
"The challenge was to engineer a molecule that could deliver superior performance at a low use level, while driving skin longevity," said Joshua Britton, PhD, Founder and CEO of Debut.
Clinical results for a widespread skin concern
Debut reports that, in a 12-week clinical study, 97% of participants showed improvement in hyperpigmentation, while 88% demonstrated improvements in overall skin brightening.
The company also states that the ingredient has been designed to work across all skin tones and address uneven pigmentation while remaining gentle on the skin.
Hyperpigmentation remains one of the most common skincare concerns globally. Debut cites a 2025 Journal of Investigative Dermatology study involving 48,000 adults across 34 countries, in which half of respondents reported experiencing at least one pigmentary disorder, including melasma, sunspots and other forms of uneven pigmentation.
Available in the US
PNar is now available to brand partners through Debut’s US formulation business.
The launch reflects a broader industry trend toward biotech-designed active ingredients developed through AI-assisted discovery platforms, as cosmetic manufacturers increasingly seek novel molecules that combine clinically substantiated efficacy with evolving regulatory and formulation requirements.
